静脉应用核小体H2B表位肽防治小鼠实验性系统性红斑狼疮的研究  

Prevention and treatment of experimental mice systemic lupus erythematosus by peptide with nucleosome H2B epitopes

作　　者：郝进[1] 郝飞[1] 钟白玉[1] 唐书谦[1] 杨希川[1] 徐云升[1] 叶庆佾[1] 

机构地区：[1]第三军医大学附属西南医院皮肤性病科,重庆400038

出　　处：《中华风湿病学杂志》2005年第2期65-67,i001,共4页Chinese Journal of Rheumatology

基　　金：国家自然科学基金资助项目(30200258)

摘　　要：目的探讨静脉途径应用基于核小体的表位肽防治系统性红斑狼疮(SLE)的可行性。方法以凋亡细胞诱导的SLE样症状小鼠为模型,用核小体表位肽H2B14￣28静脉途径诱导小鼠免疫耐受,观察实验小鼠自身抗体产生情况以及SLE样临床症状改善情况。结果用表位肽H2B14￣28诱导免疫耐受以后,可显著降低实验小鼠抗核抗体(ANA)、抗双链DNA(dsDNA)抗体、抗RNP抗体和抗心磷脂(ACL)抗体的产生,同时显著改善小鼠蛋白尿、白细胞低下、肾脏免疫复合物沉积程度和病理损伤程度。结论静脉途径应用核小体表位肽H2B14￣28可有效阻止实验性SLE病变的形成,基于核小体表位肽的肽疫苗的研究有可能为SLE的防治开辟一条全新的思路和途径。Objective To investigate the effects of immune tolerance induced by peptide based on nucleosome H2B epitopes in prevention and treatment of systemic lupus erythematosus (SLE). Methods Based on a model of experimental systemic lupus erythematosus induced with syngeneic apoptotic lymphocytes to BALB/c mice, immune tolerance was induced by H2B14~28, administration intravenously with H2B Th cell epitope peptide. The effects of prevention and treatment were evaluated by changes in autoantibodies and SLE-like clinical manifestations. Results The peptide of H2B14~28 was highly effective in preventing autoantibody production of SLE (such as ANA, anti-dsDNA Abs, anti-RNP Abs and ACL Abs), and ameliorating clinical manifestations. Conclusion Tolerance to nucleosome induced by H2B14~28 peptide can significantly inhibit autoantibodies production and down-regulate clinical manifestations of SLE. So it may be a new way to treat and prevent SLE by nucleosome-based immune tolerance vaccine.

关 键 词：静脉 核小体 H2B表位肽 防治 小鼠 系统性红斑狼疮 自身抗体 

分 类 号：R593.241[医药卫生—内科学]